Latest & greatest articles for screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for screening

3441. Patients with polycystic kidney disease would benefit from routine magnetic resonance angiographic screening for intracerebral aneurysms: a decision analysis

Patients with polycystic kidney disease would benefit from routine magnetic resonance angiographic screening for intracerebral aneurysms: a decision analysis Patients with polycystic kidney disease would benefit from routine magnetic resonance angiographic screening for intracerebral aneurysms: a decision analysis Patients with polycystic kidney disease would benefit from routine magnetic resonance angiographic screening for intracerebral aneurysms: a decision analysis Butler W E, Barker F G (...) , Crowell R M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Magnetic resonance angiographic imaging (MRI) screening in patients with autosomal dominant polycystic kidney disease (ADPKD). Type of intervention Screening. Economic study

1996 NHS Economic Evaluation Database.

3442. A comparison of screening strategies for elevated blood lead levels

A comparison of screening strategies for elevated blood lead levels A comparison of screening strategies for elevated blood lead levels A comparison of screening strategies for elevated blood lead levels Campbell J R, Paris M, Schaffer S J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Screening strategies for the detection of elevated blood lead levels. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population A hypothetical cohort of asymptomatic children aged 6 or younger. Setting Hospital. The economic study was carried out in New York, USA. Dates to which data relate The main effectiveness data were taken from published data of previously completed studies, and unpublished

1996 NHS Economic Evaluation Database.

3443. Ante-natal screening for hepatitis B surface antigen: an appraisal of its value in a low prevalence area

Ante-natal screening for hepatitis B surface antigen: an appraisal of its value in a low prevalence area Ante-natal screening for hepatitis B surface antigen: an appraisal of its value in a low prevalence area Ante-natal screening for hepatitis B surface antigen: an appraisal of its value in a low prevalence area Dwyer M J, McIntyre P G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Routine antenatal screening for maternal hepatitis B surface antigen (HBsAg) versus targeted screening of women with an obvious risk factor followed by vaccine treatment. Type of intervention Screening and treatment. Economic study type Cost-effectiveness study. Study population All pregnant women in East Anglia. Setting The setting

1996 NHS Economic Evaluation Database.

3444. Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs

Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs Durand-Zaleski I, Schlegel N, Blum Boisgard C, Uzan S, Dreyfus M, Kaplan C (...) of fetomaternal alloimmune thrombocytopenia (FMAIT)/Neonatal alloimmune thrombocytopenia (NAIT). This is a disease caused by the maternal immunisation against foetal platelet antigens which can occur when the mother has the antigen HPA-1b and the father is HPA-1a. The techniques employed were: radioimmunoassay and monoclonal antibody-specific immobilization of platelet antigen. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Primiparous women were included

1996 NHS Economic Evaluation Database.

3445. The cost-effectiveness of human immunodeficiency virus screening in pregnancy

The cost-effectiveness of human immunodeficiency virus screening in pregnancy The cost-effectiveness of human immunodeficiency virus screening in pregnancy The cost-effectiveness of human immunodeficiency virus screening in pregnancy Ecker J L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology HIV screening in pregnancy. Type of intervention Primary prevention; screening. Economic study type Cost-effectiveness analysis. Study population Hypothetical cohort of women entering prenatal care before 34 weeks' gestation. This gestational age was the cut-off used to exclude subjects from the recent trial of zidovudine in pregnancy conducted by the National Institutes of Health (NIH). Setting Antenatal clinic of a University hospital

1996 NHS Economic Evaluation Database.

3446. UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening. Full Text available with Trip Pro

UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening. To compare one view (oblique) and two view (oblique and craniocaudal) mammography in breast cancer screening.Randomised controlled trial.Nine breast screening centres in England.40,163 women aged 50-64 attending their first breast screening examination.Women were randomised to have one view mammography, two view mammography, or two view mammography in which one view was read by one reader (...) with one view (8.16%) mammography. The cost of two view screening was higher (26.46 pounds compared with 22.00 pounds per examination) but the average cost per cancer detected was similar (5330 pounds compared with 5310 pounds) and the marginal cost per extra cancer detected with two views was similar to the average cost (5400 pounds).Two view mammography is medically more effective than one view; it detects more cancers and reduces recall rates; it is also similarly cost effective financially.

1995 BMJ Controlled trial quality: predicted high

3447. Antenatal screening for carriers of cystic fibrosis: randomised trial of stepwise v couple screening. Full Text available with Trip Pro

Antenatal screening for carriers of cystic fibrosis: randomised trial of stepwise v couple screening. To perform a rigorous comparative evaluation of stepwise and couple approaches to antenatal carrier screening for cystic fibrosis.Pragmatic randomised trial.Hospital antenatal clinic serving a regional population.2002 women (couples) attending for booking antenatal visit at less than 17 weeks' gestation with no family history of cystic fibrosis.Offering counselling and carrier testing (...) for cystic fibrosis, either to women in the first instance (stepwise) or to couples (couple screening).Uptake rates; anxiety; knowledge of cystic fibrosis and carrier status (both partners); attitudes to health, pregnancy, the baby, and screening (both partners); and uptake of carrier testing by relatives.Uptake of screening was the same for both approaches (90%). After delivery most women remembered test results and their meaning, but 53/253 (21%) of those with negative results of couple testing had

1995 BMJ Controlled trial quality: uncertain

3448. Screening for cardiovascular risk: cost-benefit considerations in a comparison of total cholesterol measurements and two compound blood lipid indices

Screening for cardiovascular risk: cost-benefit considerations in a comparison of total cholesterol measurements and two compound blood lipid indices Screening for cardiovascular risk: cost-benefit considerations in a comparison of total cholesterol measurements and two compound blood lipid indices Screening for cardiovascular risk: cost-benefit considerations in a comparison of total cholesterol measurements and two compound blood lipid indices Berg J E Record Status This is a critical (...) Screening. Economic study type Cost-effectiveness analysis. Study population All healthy 40 years old adults with cholesterol level equal or greater than 6 mmol Setting Occupational health service. The economic study was carried out in Norway. Dates to which data relate Effectiveness data related to the period 1991 to 1993. 1992 cost and resource data were used. Source of effectiveness data The effectiveness data were based on a review of previously completed studies (Berg and Hostmark, 1993; Stampfer

1995 NHS Economic Evaluation Database.

3449. Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness

Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness Adams P C, Kertesz A E, Valberg L S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Screening for hemochromatosis with transferrin saturation as the initial screening test, which is repeated in a fasting state if abnormal findings result from the former. Children with abnormal findings in the latter test, then undergo a serum ferritin test undertaken on the same blood sample. Those patients with high transferrin saturation and abnormal findings from ferritin

1995 NHS Economic Evaluation Database.

3450. Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database

Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database Adams P C, Gregor J C, Kertesz A E, Valberg L S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Screening blood donors for hereditary hemochromatosis. Type of intervention Screening, diagnosis and treatment. Economic study type Cost-utility analysis. Study population Hypothetical cohort of 10,000 voluntary blood donors. Setting Hospital and primary care. The study was carried out in Ontario, Canada

1995 NHS Economic Evaluation Database.

3451. Community-based tuberculin screening in Montreal: a cost-outcome description

Community-based tuberculin screening in Montreal: a cost-outcome description Community-based tuberculin screening in Montreal: a cost-outcome description Community-based tuberculin screening in Montreal: a cost-outcome description Adhikari N, Menzies R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Community-based tuberculin screening and treatment. Type of intervention Secondary prevention via screening and follow-up treatment. Economic study type Cost-effectiveness analysis. Study population Students in grades 6 and 10, first-year health professional students and workers aged 18 to 25 years in a number of workforces. Setting The practice setting was hospital (inpatient and outpatient). The economic study was carried out

1995 NHS Economic Evaluation Database.

3452. Breast cancer screening through mammography. IPE-95/05 (Public report)

Breast cancer screening through mammography. IPE-95/05 (Public report) Breast cancer screening through mammography. IPE-95/05 (Public report) Breast cancer screening through mammography. IPE-95/05 (Public report) Conde Olasagasti J L, Gonzalez Enriquez J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Conde Olasagasti J L, Gonzalez (...) Enriquez J. Breast cancer screening through mammography. IPE-95/05 (Public report) Madrid: Agencia de Evaluacion de Tecnologias Sanitarias (AETS). 1995 Authors' objectives To summarise the available evidence on the use of mammography in mass screening for breast cancer. Authors' conclusions The available evidence regarding the efficacy of breast cancer screening by means of periodic mammography in women of 50 years of age or more, is solid and consistent, and is based fundamentally on the results

1995 Health Technology Assessment (HTA) Database.

3453. Opportunity of a screening program of Hemochromatosis in France

Opportunity of a screening program of Hemochromatosis in France Opportunity of a screening program of Hemochromatosis in France Opportunity of a screening program of Hemochromatosis in France Bernard A, Brasselet S, Charvet-Protat S, Fleurette F Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bernard A, Brasselet S, Charvet-Protat S (...) , Fleurette F. Opportunity of a screening program of Hemochromatosis in France. Paris: Agence Nationale pour le Developpement de l'Evaluation Medicale (ANAES) 1995: 83 Authors' objectives Hemochromatosis is one of the most frequent genetic diseases (1.5 to 3 cases per 1000). It is characterised by a progressive iron overload which gives organ damage and dysfunction (liver, heart, pancreas). Blood testing is available for detection of this iron overload, and there is a treatment (phlebotomy). The French

1995 Health Technology Assessment (HTA) Database.

3454. Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review

Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review Hanley J A, McGregor M Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hanley J A, McGregor M. Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review. Montreal: Conseil d'Evaluation des Technologies de la Sante du Quebec (CETS). 1995 Authors' objectives To evaluate the benefits, adverse health effects and costs of screening asymptomatic men for cancer of the prostate. Authors' conclusions From

1995 Health Technology Assessment (HTA) Database.

3455. The screening of primary open-angle glaucoma - systematic review

The screening of primary open-angle glaucoma - systematic review The screening of primary open-angle glaucoma - systematic review The screening of primary open-angle glaucoma - systematic review Boivin J F, McGregor M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Boivin J F, McGregor M. The screening of primary open-angle glaucoma (...) - systematic review. Montreal: Conseil d'Evaluation des Technologies de la Sante du Quebec (CETS). 1995 Authors' objectives To assess the cost-effectiveness of a possible formal screening program for open-angle glaucoma in the province of Quebec. Authors' conclusions The analysis do not support the setting up of a formal glaucoma screening program in Quebec, both because of the high degree of uncertainty and because of the high cost such a programwould entail. However, there already exists a significant

1995 Health Technology Assessment (HTA) Database.

3456. Costs and effectiveness of prostate cancer screening in elderly men

Costs and effectiveness of prostate cancer screening in elderly men Costs and effectiveness of prostate cancer screening in elderly men Costs and effectiveness of prostate cancer screening in elderly men Office of Technology Assessment Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Office of Technology Assessment. Costs and effectiveness of prostate cancer screening in elderly men. Washington DC: U. S. Congress. Office of Technology Assessment (OTA) 1995: 130 Authors' objectives To examine the effectiveness, safety, and costs of screening for prostate cancer among asymptomatic men over 65 years in order to analyze the implications of a potential screening benefit under the U. S. Medicare program. Authors' conclusions Given the state of current

1995 Health Technology Assessment (HTA) Database.

3457. Approach to the utilization of screening mammography in two health regions

Approach to the utilization of screening mammography in two health regions Approach to the utilization of screening mammography in two health regions Approach to the utilization of screening mammography in two health regions Almazan C, Borras JM, de la Puente ML, Gimenez A, Granados A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Almazan C, Borras JM, de la Puente ML, Gimenez A, Granados A. Approach to the utilization of screening mammography in two health regions. Barcelona: Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA). 1995 Authors' objectives To know the current utilization trends of screening mammography regarding the criteria of starting age of the screening, as defined in the Catalan Health Plan, and the activity of the mammographers. Methods:Cross-sectional study design. Authors

1995 Health Technology Assessment (HTA) Database.

3458. Effectiveness of interventions to enhance physician screening for breast cancer

Effectiveness of interventions to enhance physician screening for breast cancer Effectiveness of interventions to enhance physician screening for breast cancer Effectiveness of interventions to enhance physician screening for breast cancer Mandelblatt J, Kanetsky P A Authors' objectives To review articles assessing the effectiveness of interventions to enhance physician breast cancer screening behaviour. Searching MEDLINE was searched for studies published between January 1980 and April 1993 (...) . The search terms included 'preventive health care services', 'clinical breast examination', 'breast', 'mammography', 'screening', 'cancer prevention' and 'periodic health examination'. A full list of search terms was included in the paper. Additional studies were sourced from Current Contents (November 1992 to April 1993) and the reference lists of identified studies. Study selection Study designs of evaluations included in the review Controlled trials with concurrent arms were eligible if they included

1995 DARE.

3459. Screening for abdominal aortic aneurysms during lower extremity arterial evaluation in the vascular laboratory

Screening for abdominal aortic aneurysms during lower extremity arterial evaluation in the vascular laboratory Screening for abdominal aortic aneurysms during lower extremity arterial evaluation in the vascular laboratory Screening for abdominal aortic aneurysms during lower extremity arterial evaluation in the vascular laboratory Wolf Y G, Otis S M, Schwend R B, Bernstein E F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Abdominal aortic aneurysm (AAA) screening during lower extremity arterial evaluation. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Lower extremity arterial examinations between 1990 - 1993. After regular noninvasive lower extremity arterial

1995 NHS Economic Evaluation Database.

3460. Screening for colorectal cancer: what are the costs?

Screening for colorectal cancer: what are the costs? Screening for colorectal cancer: what are the costs? Screening for colorectal cancer: what are the costs? Weller D, Moss J, Hiller J, Thomas J, Edwards J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology The fecal occult blood test (FOBT) as a method for screening for the detection of colorectal cancer. Type of intervention Screening. Economic study type Cost-effectiveness study. Study population Patients screened for colorectal cancer. Setting The practice setting is the community with follow up in general practice and institutions as required. The study was undertaken in South Australia. Dates to which data relate Effectiveness and resource data were collected

1995 NHS Economic Evaluation Database.